Passage of VIP / PACAP / Secretin Family Across the Blood-Brain Barrier: Therapeutic Effects
The DOI matches its Crossref record.
Abstract
In recent years, VIP/PACAP/secretin family has special interest. Family members are vasoactive intestinal peptide (VIP), pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, glucagon, glucagon like peptide-1 (GLP(1)), GLP(2), gastric inhibitory peptide (GIP), growth hormone releasing hormone (GHRH or GRF), and peptide histidine methionine (PHM). Most of the family members present both in central nervous system (CNS) and in various peripheral tissues. The family members that are released into blood from periphery, especially gut, circulate the brain and they can cross the blood brain barrier. On the other hand, some of the members of this family that present in the brain, can cross from brain to blood and reach the peripheral targets. VIP, secretin, GLP(1), and PACAP 27 are transported into the brain by transmembrane diffusion, a non-saturable mechanism. However, uptake of PACAP 38 into the brain is saturable mechanism. While there is no report for the passage of GIP, GLP(2), and PHM, there is only one report that shows, glucagon and GHRH can cross the BBB. The passage of VIP/PACAP/secretin family members opens up new horizon for understanding of CNS effects of peripherally administrated peptides. There is much hope that those peptides may prove to be useful in the treatment of serious neurological diseases such as Alzheimer's disease, amyotropic lateral sclerosis, Parkinson's disease, AIDS related neuropathy, diabetic neuropathy, autism, stroke and nerve injury. Their benefits in various pathophysiologic conditions undoubtly motivate the development of a novel drug design for future therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Blood-brain barrier transport of cytokines: a mechanism for neuropathology
Banks, W. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381684 · Cited by 534
PACAP38 induces migraine-like attacks in patients with migraine without aura
Schytz, H. W., Birk, S., Wienecke, T., Kruuse, C., Olesen, J., & Ashina, M. (2009) · Brain · doi:10.1093/brain/awn307 · Cited by 494
Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., & Isacson, O. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi178 · Cited by 361
“Interestingly, several neuropeptides, including PACAP and VIP, are known to be transported through the blood brain barrier via transmembrane diffusion (76), thus increasing their potential to be utilized in therapies for PD.”
BackgroundThe role of G protein-coupled receptors in the pathology of Alzheimer's disease
Thathiah, A., & De Strooper, B. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2977 · Cited by 288
“Although the molecular mechanism of this effect has not been elucidated, neuropeptide hormones such as PACAP27 and PACAP38 display a high flux rate across the blood–brain barrier (BBB”
BackgroundDelivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
“NN Dogrukol-Ak et al. (2004)”
Metadata
- Authors
- Dogrukol-Ak, D., Tore, F., & Tuncel, N.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-05-01
- Volume
- 10
- Issue
- 12
- Pages
- 1325-1340
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2163441473
- Cited by
- 105
- References
- 0
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Passage of VIP / PACAP / Secretin Family Across the Blood-Brain Barrier: Therapeutic Effects. https://app.cochat.ai/papers/10.2174/1381612043384934
- The paper
- Dogrukol-Ak, D., Tore, F., & Tuncel, N. (2004). Passage of VIP / PACAP / Secretin Family Across the Blood-Brain Barrier: Therapeutic Effects. Current Pharmaceutical Design. https://doi.org/10.2174/1381612043384934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.